Get to know our clinical trials
Phase 2b/3, adaptive, randomized, active-controlled clinical trial to evaluate the efficacy, safety, and tolerability of povetacicept versus a calcineurin inhibitor in the treatment of primary membranous nephropathy.
EL OBJETO DE ESTA INVESTIGACIÓN ES EVALUAR SI EL FÁRMACO DEL ESTUDIO ES SEGURO Y SI PUEDE MEJORAR LA NMP Y ALIVIAR LOS SÍNTOMAS DE LOS PACIENTES CON ESTA ENFERMEDAD. LA NMP ES UNA RARA ENFERMEDAD AUTOINMUNITARIA QUE AFECTA A LOS RIÑONES Y QUE SE PRODUCE CUANDO CIERTOS AUTOANTICUERPOS PRESENTES EN LA SANGRE (COMO EL AUTOANTICUERPO ANTI-PLA2R, QUE ES PRODUCIDO POR EL SISTEMA INMUNITARIO Y QUE, POR ERROR, ATACA A LAS CÉLULAS Y TEJIDOS SANOS DEL ORGANISMO) ATACAN A LAS UNIDADES DE FILTRACIÓN DEL RIÑÓN, LO QUE LAS DAÑA, PERDIENDO PARTE DE SU CAPACIDAD PARA FILTRAR LOS DESECHOS
Technical Summary
- A PHASE 2B/3, ADAPTIVE, RANDOMIZED, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF POVETACICEPT VERSUS A CALCINEURIN INHIBITOR IN THE TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY.
- Code EudraCT: 2025-521661-27-00
- Protocol number: VX24-AIS-D10
- Promoter: Vertex Pharmaceuticals
- Molecule/Drug: Povetacicept
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.